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Objectives. This study sought to evaluate the relation between
antiplatelet agent (APA) use and survival and morbidity from
cardiac disease in patients with left ventricular (LV) systolic
dysfunction.
Background. APAs play an important role in the prevention
and treatment of coronary disease. Their effects in patients with
LV systolic dysfunction are unknown.
Methods. We reviewed data on APA use in 6,797 patients
enrolled in the Studies of Left Ventricular Dysfunction (SOLVD)
trial and analyzed the relation between their use and all-cause
mortality as well as the combined end point of death or hospital
admission for heart failure (HF). We used Cox regression to
adjust for differences in baseline characteristics and to test for the
interaction between APA use and selected patient variables in
relation to outcome.
Results. APA use (46.3% of patients) was associated with
significantly reduced mortality from all causes (adjusted hazard
ratio [HR] 0.82, 95% confidence interval [CI] 0.73 to 0.92, p 5
0.0005) and reduced risk of death or hospital admission for HF
(adjusted HR 0.81, 95% CI 0.74 to 0.89, p < 0.0001) but was not
influenced by trial assignment, gender, LV ejection fraction, New
York Heart Association class or etiology. A strong interaction was
observed among APA use, randomization group and all-cause
mortality. The association between APA use and survival was not
observed in the enalapril group, nor was an enalapril benefit on
survival detectable in patients receiving APAs at baseline. How-
ever, randomization to enalapril therapy significantly reduced the
combined end point of death or hospital admission for HF in APA
users.
Conclusions. In patients with LV systolic dysfunction, use of
APAs is associated with improved survival and reduced morbidity.
This association is retained after adjustment for baseline charac-
teristics. APA use is associated with retained but reduced benefit
from enalapril.
(J Am Coll Cardiol 1998;31:419–25)
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Heart failure (HF) is a leading cause of death among patients
with cardiovascular diseases. Despite the use of angiotensin-
converting enzyme (ACE) inhibitors, the annual mortality rate
continues to be as high as 36% (1). Aspirin has proved to be a
beneficial drug for the primary and secondary prevention of
coronary events and in the treatment of acute coronary
syndromes (2–5). The antiplatelet effects of this agent are
thought to mediate its efficacy in preventing acute coronary
thrombosis and possibly prevention of progression of athero-
sclerosis (6,7). The effect of aspirin therapy in patients with HF
of various etiologies has not been adequately tested. Of the
studies that evaluated aspirin use after myocardial infarction
(MI), only the Aspirin in Myocardial Infarction Study (AMIS)
(8) and Persantine Aspirin Reinfarction Study II (9) trials
reported the influence of baseline characteristics on outcome,
and no conclusions can be drawn regarding the use of aspirin
in patients with chronic HF or nonischemic left ventricular
(LV) systolic dysfunction, or both.
Although aspirin therapy may prevent further ischemic
insults in patients with ischemic cardiomyopathy, its effects on
prostaglandins may adversely affect hemodynamic function.
Aspirin antagonizes the beneficial effects of antihypertensive
therapy (10–12), and may reduce systemic vasodilatory re-
serve. Aspirin also decreases glomerular filtration pressure,
reducing sodium and water excretion and blunting the effect of
diuretic drugs (13).
To explore the effect of aspirin and other antiplatelet agents
(APAs) on outcome in patients with HF, we analyzed data
from the Studies of Left Ventricular Dysfunction (SOLVD)
concerning use of APAs, particularly the relation between use
of these agents and survival.
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Methods
Patients. SOLVD was a multicenter, randomized, double-
blind, placebo-controlled investigation that studied the effect
of enalapril on morbidity and mortality in patients with LV
systolic dysfunction, defined as LV ejection fraction (LVEF)
#0.35 (14,15). Patients receiving treatment other than ACE
inhibitors for symptoms of HF were enrolled in the treatment
trial; patients without such symptoms were enrolled in the pre-
vention trial (16). Patients were ineligible if they were .80 years
of age or had any of the following: hemodynamically serious
valvular heart disease requiring operation, unstable angina pec-
toris, angina thought to be severe enough to require revascular-
ization procedures, MI during the previous month, severe pulmo-
nary disease, serum creatinine levels .177 mmol/liter (2 mg/dl) or
any other disease that might substantially shorten survival or
impede participation in a long-term trial. Ventricular function
was assessed by contrast angiography, radionuclide ventriculog-
raphy or two-dimensional echocardiography. The baseline study
visit included a comprehensive review of medical history, and
patients were specifically asked whether they were taking certain
medications regularly, including APAs and those shown in Table
1. After randomization to enalapril or placebo therapy, patients
were regularly evaluated, and their clinical status, including the
development of HF, hospital admissions, adherence to study
regimen and adverse effects, was recorded at each follow-up visit.
For patients who died or were admitted to the hospital, the cause
of death or the primary reason for hospital admission was
evaluated and classified by an investigator, who had no knowledge
of the study treatment.
We reviewed the data on APA use, including aspirin and
dipyridamole, at baseline. All patients in both trials with
complete data were included in the analysis. The end points of
all-cause mortality, death or hospital admission for any cardiac
event (HF, acute coronary syndromes or arrhythmia), death or
hospital admission for HF, cardiovascular death, sudden death
without antecedent worsening HF, death due to HF and fatal
MI were analyzed.
Statistical analysis. The primary outcome measures were
death and length of survival (time from entry into the study
until death, end of study or loss to follow-up). Risk factors of
primary interest were APA use randomization to enalapril
therapy and trial (treatment or prevention). The chi-square
test for independence was used to analyze unadjusted mortal-
ity rates and to calculate relative risk (RR) and 95% confi-
dence interval (CI). A p value , 0.05 was considered signifi-
cant. Kaplan-Meier survival analysis was used to examine
duration of survival, with log rank tests to compare survival
analysis curves between subsets of patients.
Cox regression was used to adjust for potential influence of
confounding factors on survival time and included age, gender,
etiology, trial assignment, study drug randomization, LVEF,
New York Heart Association functional class, history of an-
gina, history of atrial fibrillation, history of cerebrovascular
disease and baseline drug therapy with warfarin, digitalis or
diuretic drugs. Results are reported as adjusted hazard ratio
(HR) with 95% CI. The computer statistical software package
SPSS (version 7.5) was used for all analyses.
Results
Patients. Of 6,797 patients enrolled (2,569 in the treatment
trial, 4,228 in the prevention trial), data from 6,512 were
Abbreviations and Acronyms
ACE 5 angiotensin converting enzyme
APA 5 antiplatelet agent
CI 5 confidence interval
HF 5 heart failure
HR 5 hazard ratio
LV 5 left ventricular
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
RR 5 relative risk
SOLVD 5 Studies of Left Ventricular Dysfunction
Table 1. Baseline Clinical Characteristics and Drug Therapy for
Antiplatelet Agent Users and Nonusers in the Studies of Left
Ventricular Dysfunction Combined Trial*
APA
Users
(n 5 3,017)
APA
Nonusers
(n 5 3,495)
p
Value
Randomization group
(% randomized to
enalapril therapy)
50.4 49.7 0.6
Age (yr) 60.0 6 9.6 59.7 6 10.8 0.2
Men 88.5 83.2 , 0.0001
LVEF (%) 28.1 6 5.7 26.1 6 6.6 , 0.0001
NYHA functional class , 0.0001
I 50.6 39.8
II 40.4 44.6
III 8.7 14.5
IV 0.2 1.1
History of
Angina 66.2 49.6 , 0.0001
Atrial fibrillation 3.5 9.0 , 0.0001
Cerebrovascular disease 7.2 6.1 0.06
Diabetes mellitus 19.5 19.4 0.9
Hypertension 38.3 39.8 0.2
Smoking 80.2 76.7 0.0005
Etiology
Ischemic 91.2 67.9 , 0.0001
Nonischemic 8.8 32.1 , 0.0001
Baseline drug therapy
Antiarrhythmic agents 14.9 19.7 , 0.0001
Anticoagulant agents 4.9 20.4 , 0.0001
Beta-blockers 21.8 14.1 , 0.0001
Digitalis 23.5 41.8 , 0.0001
Diuretic drugs 30.8 53.3 , 0.0001
Potassium supplements 16.0 29.0 , 0.0001
Nitrates 37.0 33.2 0.001
*Baseline data were missing in 285 patients. Data presented are mean
value 6 SD or percent of patients. APA 5 antiplatelet agent; LVEF 5 ejection
fraction; NYHA 5 New York Heart Association.
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considered in the final analysis; 285 patients (4.2%) were
excluded because of missing baseline information. The mean
follow-up period was 41.4 months in the treatment trial and
37.4 months in the prevention trial. The clinical characteristics
of APA users and nonusers in the combined trial are shown in
Table 1. Of the total population, 46.3% of patients reported
using APA and 53.7% did not use APAs at the time of
randomization. There was no significant difference in the mean
age between the two groups. The proportion of male patients
was higher in the APA users group. Patients taking APAs
generally had a higher LVEF and were in a lower mean
functional class, and most had ischemic heart disease. They
were less likely to have atrial fibrillation or to be using
antiarrhythmic agents, anticoagulant agents, digitalis or di-
uretic drugs. Most (.95%) patients receiving APAs were
taking aspirin.
All-cause mortality. By the end of the study, in the com-
bined trial, there were 548 deaths in the APA users group
(18.2%) compared with 997 in the APA nonusers group
(28.5%) (RR 0.64, 95% CI 0.58 to 0.70 p , 0.0001). Mortality
risk reduction in APA users was present in both the treatment
trial (RR 0.83, 95% CI 0.74 to 0.93, p 5 0.0001) and the
prevention trial (RR 0.68, 95% CI 0.59 to 0.79, p , 0.0001).
Mean survival time in the combined trial was 1,590 days in
APA users versus 1,470 days in nonusers (p , 0.0001) (treat-
ment trial: 1,282 days vs. 1,208 days, p 5 0.008; prevention
trial: 1,673 days vs. 1,614 days, p 5 0.0002).
After adjusting for confounding factors, APA use emerged
as a significant predictor of favorable outcome (Fig. 1). In the
combined trial, HR for all-cause mortality was 0.82 (95% CI
0.73 to 0.92, p 5 0.0006) in users compared with nonusers
(Table 2). This benefit was seen in the treatment and preven-
tion trials when analyzed separately (Table 3).
Causes of cardiac death. Of 1,545 deaths in the combined
trial population, 1,357 were due to cardiovascular causes (484
in the APA users group vs. 873 in the nonusers group; RR 0.64,
95% CI 0.58 to 0.71, p , 0.0001), of which there were 1,273
cardiac deaths (447 in the APA users group vs. 826 in the
nonusers group; RR 0.63, 95% CI 0.56 to 0.70, p , 0.0001). All
three modes of cardiac death (sudden death not associated
with worsening HF, death associated with worsening HF, fatal
MI) were reduced.
After adjusting for confounding variables, APA use was no
longer associated with a reduction in death associated with
worsening of HF but remained associated with a reduction in
the other causes of cardiac death (Table 2). Noncardiac
vascular deaths, including fatal strokes and pulmonary embo-
lism, were not different between groups. APA use was associ-
ated with a similar reduction in the risk of cardiac death in
both trials when analyzed separately.
Death or hospital admission for cardiac events. In the
combined group, 42.6% of APA users experienced death or
hospital admission for any cardiac event, and 26.4% experi-
enced death or hospital admission for HF, compared with
54.5% and 40.6% in the nonusers group, respectively (p ,
0.0001 for both). The mean time to death or hospital admission
for any cardiac event was 1,187 days for APA users versus
1,053 days for nonusers (p , 0.0001), and the mean time to
death or hospital admission for HF was 1,455 days for APA
users versus 1,271 days for APA nonusers (p , 0.0001).
Tables 2 and 3 show the HRs for the combined, treatment
Figure 1. Adjusted all-cause mortality in users (APA1) and nonusers
(APA2) of APAs in the combined SOLVD trial.
Table 2. Adjusted Hazard Ratios of Mortality, Morbidity and Cause
of Death in Antiplatelet Agent Users Versus Nonusers in the
Studies of Left Ventricular Dysfunction Combined Trial
End Point
Adjusted HR
95% CI
p
Value
All-cause mortality 0.82 (0.73–0.92) 0.0006
Cardiac death 0.80 (0.71–0.91) 0.0006
Sudden death not preceded
by worsening of HF
0.78 (0.63–0.97) 0.02
Death associated with HF 0.92 (0.77–1.10) 0.4
Fatal MI 0.58 (0.42–0.79) 0.0006
Noncardiovascular death 1.27 (0.79–2.04) 0.3
Death or hospital admission
For any cardiac event 0.86 (0.80–0.93) 0.0002
For HF 0.81 (0.74–0.89) , 0.0001
CI 5 confidence interval; HF 5 heart failure; HR 5 hazard ratio; MI 5
myocardial infarction.
Table 3. Adjusted Hazard Ratios of Mortality and Morbidity in
Antiplatelet Agent Users Versus Nonusers in the Studies of Left
Ventricular Dysfunction Prevention and Treatment Trials
End Point
Adjusted HR
(95% CI)
p
Value
Prevention trial
All-cause mortality 0.79 (0.67–0.94) 0.008
Death or hospital admission
For any cardiac event 0.86 (0.77–0.96) 0.005
For HF 0.78 (0.68–0.90) 0.0006
Treatment trial
All-cause mortality 0.86 (0.75–0.98) 0.04
Death or hospital admission
For any cardiac event 0.88 (0.78–0.98) 0.02
For HF 0.86 (0.76–0.97) 0.01
Abbreviations as in Table 2.
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and prevention trials. After adjusting for confounding vari-
ables, APA use was associated with a statistically significant
reduction in combined end points of death or hospital admis-
sion for any cardiac event and death or hospital admission for
HF (Fig. 2).
Effect of APA use in different subgroups. The relation
between APA use and the various end points was analyzed by
age, gender, etiology, functional class, LVEF and randomiza-
tion to enalapril therapy. Interaction terms were introduced
into the Cox regression analysis, and adjustment for confound-
ing variables was performed. The presence of a significant
interaction (p , 0.05) was considered to indicate dependence
of the association between APA use and survival on the
presence or variation in one of these variables. Gender,
etiology and functional class had no influence on the relation
between APA use and any of the end points (Table 4). No such
influence was seen when both trials were analyzed separately.
Despite the absence of a statistically significant interaction
with etiology, a significant relation between APA use and
survival was seen only in the ischemic group after adjustment
for confounding variables. In the nonischemic group, there was
a nonsignificant trend toward improved survival among pa-
tients receiving APA (p 5 0.3). However, the number of
patients was small (n 5 1,385), and the frequency of APA use
was lower in this group (only 19.1% reported using APAs).
The nonischemic group, therefore, lacked sufficient power to
detect a statistically significant difference between APA users
and nonusers.
There was a significant interaction among APA use, age
and all-cause mortality (p 5 0.02). This interaction was present
within each trial, separately and after adjusting for confound-
ing variables. The survival benefit associated with APA use was
lower in magnitude with increasing patient age.
Interaction between APA and enalapril therapy. When the
APA–enalapril interaction term was tested in the Cox regres-
sion model in the combined trial, it was found to be a
significant predictor of all-cause mortality (p 5 0.0005). This
interaction was explored further by analyzing mortality rates by
APA use and randomization to enalapril therapy, with adjust-
ment for baseline differences.
Tables 5 and 6 show the HRs (with 95% CIs) for the
combined population. Table 5 shows the absence of a relation
between APA use and survival among patients randomized to
enalapril therapy. In contrast, Table 6 shows that in patients
with baseline use of APA, a significant survival benefit of
enalapril could not be identified, although enalapril-induced
reduction in the combined end point of death or hospital
admission for HF persisted. Use of enalapril in these patients
was associated with an HR of 0.81 for this end point, which was
statistically significant.
When each trial was analyzed separately, significant inter-
Figure 2. Adjusted death or hospital admission for HF in users
(APA1) and nonusers (APA2) of APAs in the combined SOLVD
trial.
Table 4. Interaction Between Antiplatelet Agent Use and Selected
Patient Variables in Relation to End Points (reported as p values)
in the Studies of Left Ventricular Dysfunction Combined Trial
Variable
End Point
All-Cause
Mortality
Death or Hospital
Admission
For Any
Cardiac
Cause For HF
Age 0.02 0.8 0.002
Gender 0.3 0.9 0.1
Etiology 0.8 0.4 0.3
NYHA functional class 0.2 1.0 0.08
LVEF 0.2 0.4 0.4
Randomization group 0.0006 0.8 0.09
Trial 0.3 0.8 0.2
Abbreviations as in Tables 1 and 2.
Table 5. Adjusted Hazard Ratios of Mortality and Morbidity in
Antiplatelet Agent Users Versus Nonusers in the Studies of Left
Ventricular Dysfunction Combined Trial Patients Grouped by
Drug Randomization
End Point
Enalapril Arm
[adjusted HR
(95% CI)]
Placebo Arm
[adjusted HR
(95% CI)]
p Value
(significance of
interaction)
All-cause mortality 1.00
(0.85–1.17)
0.68
(0.58–0.80)
0.0005
Death or hospital
admission for HF
0.88
(0.76–1.01)
0.77
(0.68–0.87)
0.09
Abbreviations as in Table 2.
Table 6. Adjusted Hazard Ratios of Mortality and Morbidity in
Patients Randomized to Enalapril Versus Placebo Therapy Grouped
by Antiplatelet Agent Use
End Point
APA Users
[adjusted HR
(95% CI)]
APA Nonusers
[adjusted HR
(95% CI)]
p Value
(significance of
interaction)
All-cause mortality 1.10
(0.93–1.30)
0.77
(0.67–0.87)
0.0005
Death or hospital
admission for HF
0.81
(0.70–0.93)
0.71
(0.64–0.79)
0.09
Abbreviations as in Table 2.
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action among APA use, randomization group, and all-cause
mortality was present within the treatment trial only. Within
the prevention trial, there was no statistically significant inter-
action among APA use, randomization group and any of the
clinical end points.
Discussion
To our knowledge, the present analysis is the first to identify
an association between APA use and improved survival in
patients with LV systolic dysfunction. Users of APA in the
SOLVD trial had lower all-cause mortality and were more
likely to be free from death or hospital admission for any
cardiac event or HF. The difference between users and non-
users was statistically significant, even after adjusting for
differences in baseline characteristics between the two groups.
Findings were consistent in both the treatment and prevention
trials. Reduction in all-cause mortality was primarily derived
from a reduction in sudden death not preceded by worsening
HF and a reduction in fatal MI. There was no evidence of
beneficial association between APA use and death associated
with worsening HF or noncardiac vascular deaths in the Cox
regression model. The results of our analysis apply to patients
with chronic LV dysfunction, regardless of their symptom
status, as shown by the lack of statistical interaction between
APA use and functional class or trial assignment for all end
points and by consistency of the findings when the prevention
and treatment trials were analyzed separately.
Effect of other baseline variables. The beneficial associa-
tion between APA use and primary end points of this analysis
were present when male and female patients were analyzed
separately, and there was no interaction with LVEF. However,
this association was lower in magnitude with advancing age for
both end points (all-cause mortality and death or hospital
admission for HF, p 5 0.02 and 0.002, respectively). The
influence of age is probably multifactorial and may be related
to the presence of concomitant illnesses. Although there was
no statistical interaction between etiology and the benefit
associated with APA use, when analyzed separately, the benefit
in patients with nonischemic etiology only reached statistical
significance for the end point of death or hospital admission
for HF (p 5 0.04). There are two possible explanations for this
difference: 1) It may represent a true finding reflecting the lack
of beneficial association in this group of patients; 2) because
the number of patients in this population was small, sufficient
power to detect a statistically significant difference between
users and nonusers of APA was lacking.
Possible mechanisms of the associated benefit and role of
prostaglandins. Platelets, platelet products and thrombosis
are known to play a critical role in the pathogenesis of
cardiovascular disease. APAs, which are known to be benefi-
cial in the prevention and treatment of acute coronary syn-
dromes (2–4), inhibit the synthesis of prostaglandin G2 and,
consequently, prostaglandin endoperoxides and thromboxane
A2. Prothrombotic platelet responses are thus attenuated (17).
The role of cyclooxygenase products in the pathophysiology of
HF has not been fully elucidated. Inhibition of platelet func-
tion may be beneficial in patients with LV dysfunction, pre-
venting further episodes of myocardial ischemia and loss of
myocardium. APA use may therefore retard the progression of
HF and prolong survival. Earlier reports (18) have docu-
mented the presence of high levels of circulating vasodilatory
prostaglandins (prostacyclin [prostaglandin I2] and prostaglan-
din E2) in patients with severe chronic HF, and hemodynamic
indexes in these patients worsened with the administration of
indomethacin (18). Upregulation of prostaglandin synthesis
may be an important compensatory mechanism that counter-
acts various mediators of vasoconstriction in patients with HF.
By interfering with prostaglandin production, aspirin and other
cyclooxygenase inhibitors may exert harmful effects, com-
pounded by adverse effects on renal hemodynamic function
(13), thus decreasing responsiveness to diuretic agents.
Alternatively, more recent studies (19) have provided evi-
dence that although prostaglandins are upregulated, the bal-
ance is tilted toward the production of thromboxanes rather
than prostacyclin. In addition to causing platelet activation and
aggregation, thromboxane A2 directly causes vasoconstriction
and is thought to mediate, at least in part, the vasoconstricting
effect of angiotensin II (20). In this case, selective inhibition of
thromboxane production may be beneficial. Baur et al. (20)
found in a group of patients with class II and III ischemic HF
and LVEF ,40% that the ratio of urinary excretion of
prostacyclin metabolites to urinary excretion of thromboxane
A2 metabolites was low. This change is consistent with a shift
toward production of vasoconstricting as opposed to vasodilat-
ing prostaglandins. This ratio was increased by the administra-
tion of a single dose of 250 mg of aspirin. This relative increase
in vasodilating prostaglandins may improve vascular function
and response to vasodilators. Evidence for the latter was shown
by a recent study in patients with class III HF (21), where the
administration of 100 mg of aspirin significantly improved
sodium nitroprusside-induced increase in radial artery diame-
ter and forearm blood flow.
APA may have other effects that are important in the
setting of myocardial injury and healing, including reduction of
fibrocellular response and remodeling in the noninfarcted
myocardium (22), and inhibition of inducible nitric oxide
synthase production (23), which is augmented in patients with
HF (24–26).
APA–enalapril interaction. Within treatment trial patients
we observed a significant interaction among APA use, random-
ization to enalapril and all-cause mortality. In patients receiv-
ing APA, we were unable to document an influence of
enalapril on survival, although a beneficial effect on the
combined end point of death or hospital admission for HF was
present. There are three possible explanations for this obser-
vation: 1) It could have occurred by chance. This possibility
appears unlikely given the statistical strength of the observa-
tion. 2) APAs antagonize the effect of enalapril. This antago-
nism was demonstrated in hemodynamic studies showing that
aspirin may reverse the vasodilator effects of enalapril (27).
However, these studies used large doses of aspirin, and other
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studies failed to show similar findings (28,29). In addition,
when the levels of neurohormones were measured in the study
by Hall et al. (27), there was no evidence of reversal of changes
induced by ACE inhibitor therapy. 3) APA and enalapril may
have overlapping mechanisms of action, detracting from ben-
efit when both agents are used together. Some of the benefit of
ACE inhibitors may be mediated through their effects on
prostaglandin metabolism. Enalapril and other ACE inhibitors
inhibit the degradation of bradykinins, which are known to
enhance local production of vasodilator prostaglandins in
animals and humans (30,31). This is similar to the effect of low
doses of aspirin. The study by Baur et al. (20) supports this
mechanism of interaction. Administration of aspirin in patients
receiving enalapril did not change plasma-converting enzyme
activity, plasma angiotensin II or norepinephrine concentra-
tions. The ratio of urinary prostacyclin metabolites to throm-
boxane metabolites improved after enalapril treatment and
showed further improvement with subsequent addition of
salicylates. Furthermore, the coadministration of aspirin in the
last 4 weeks did not reverse the improvements induced by
enalapril therapy in blood pressure, plasma neurohormones,
excretion of prostaglandin metabolites, LV mass index, LVEF,
maximal aerobic capacity and maximal oxygen consumption.
The study by Jeserich et al. (21) showed that administration of
either aspirin or perindopril was associated with improvements
in vascular function. However, no additional benefit was seen
when perindopril was given to patients who were pretreated
with aspirin.
Finally, a combination of partial agonism and antagonism
between APAs and angiotensin-converting enzyme inhibitors
can explain the complex relation between these agents and
would be most consistent with our data. It is likely that APAs
and ACE inhibitors interact at multiple levels with various
degrees of agonism and antagonism, depending on their
relative concentration and on the existing balance between
vasodilating and vasoconstricting prostaglandins.
Strengths and limitations. Our analysis has important
strengths, including large sample size, prospective definition of
end points and collection of data, long follow-up time, avail-
ability of data for most patients (.95%) and consistency of the
results in different subgroups. However, it has limitations
common to cohort studies, including its retrospective nature
and lack of randomization. Our analysis also lacked data on the
dosage and consistency of APA use throughout the study
period.
Summary. The use of APA in patients with LV systolic
dysfunction is associated with improved survival and reduced
morbidity. This association is not altered by gender, etiology,
functional class or LVEF. It is reduced with advancing age
and by enalapril administration. APA use identifies a group of
patients with retained but reduced benefit from enalapril.
Further investigation is warranted to explore the basis for the
observed benefit associated with APA use and for the interac-
tion between APA and ACE inhibitors.
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